145 related articles for article (PubMed ID: 31941557)
1. Use of urinary naloxone levels in a single provider practice: a case study.
Warrington JS; Booth K; Warrington GS; Francis-Fath S
Addict Sci Clin Pract; 2020 Jan; 15(1):3. PubMed ID: 31941557
[TBL] [Abstract][Full Text] [Related]
2. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment.
Suzuki J; Zinser J; Issa M; Rodriguez C
Subst Abus; 2017; 38(4):504-507. PubMed ID: 28723256
[TBL] [Abstract][Full Text] [Related]
3. Urinary Buprenorphine, Norbuprenorphine and Naloxone Concentrations and Ratios: Review and Potential Clinical Implications.
Warrington JS; Warrington GS; Francis-Fath S; Brooklyn J
J Addict Med; 2020 Dec; 14(6):e344-e349. PubMed ID: 32530884
[TBL] [Abstract][Full Text] [Related]
4. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder.
Holt SR; Donroe JH; Cavallo DA; Tetrault JM
Drug Alcohol Depend; 2018 May; 186():171-174. PubMed ID: 29579725
[TBL] [Abstract][Full Text] [Related]
5. Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients.
Rahman N; Janardhanan A; Shikalgar S; Pirkhan MA; Canner J; Skipwith C; Noor-E-Alam M
Subst Use Misuse; 2024; 59(9):1275-1279. PubMed ID: 37950394
[TBL] [Abstract][Full Text] [Related]
6. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
Soper R; Appajosyula S; Deximo C
Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
[TBL] [Abstract][Full Text] [Related]
7. Urine naloxone concentration at different phases of buprenorphine maintenance treatment.
Heikman P; Häkkinen M; Gergov M; Ojanperä I
Drug Test Anal; 2014 Mar; 6(3):220-5. PubMed ID: 23512803
[TBL] [Abstract][Full Text] [Related]
8. Urine Spiking in a Pain Medicine Clinic: An Attempt to Simulate Adherence.
Lee D; Bazydlo LA; Reisfield GM; Goldberger BA
Pain Med; 2015 Jul; 16(7):1449-51. PubMed ID: 25522892
[No Abstract] [Full Text] [Related]
9. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
10. Quantitation of Buprenorphine, Norbuprenorphine, Buprenorphine Glucuronide, Norbuprenorphine Glucuronide, and Naloxone in Urine by LC-MS/MS.
Marin SJ; McMillin GA
Methods Mol Biol; 2016; 1383():69-78. PubMed ID: 26660175
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio.
Accurso AJ; Lee JD; McNeely J
J Subst Abuse Treat; 2017 Dec; 83():62-67. PubMed ID: 29129197
[TBL] [Abstract][Full Text] [Related]
12. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
[TBL] [Abstract][Full Text] [Related]
13. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.
Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N
J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641
[No Abstract] [Full Text] [Related]
14. Determination of buprenorphine, norbuprenorphine and naloxone in fingernail clippings and urine of patients under opioid substitution therapy.
Tzatzarakis MN; Vakonaki E; Kovatsi L; Belivanis S; Mantsi M; Alegakis A; Liesivuori J; Tsatsakis AM
J Anal Toxicol; 2015 May; 39(4):313-20. PubMed ID: 25663675
[TBL] [Abstract][Full Text] [Related]
15. A Descriptive analysis of urine drug screen results in patients with opioid use disorder managed in a primary care setting.
Sobel HG; Warrington JS; Francis-Fath S; Crocker AM; Berger CA
Addict Sci Clin Pract; 2021 Sep; 16(1):59. PubMed ID: 34593036
[TBL] [Abstract][Full Text] [Related]
16. Differential diagnosis for a stable patient maintained on buprenorphine who gives a urine toxicology screen negative for buprenorphine.
Sethi R; Petrakis I
Am J Addict; 2014; 23(3):318-9. PubMed ID: 24724891
[No Abstract] [Full Text] [Related]
17. 48-hour Induction of Transdermal Buprenorphine to Sublingual Buprenorphine/Naloxone: The IPPAS Method.
Azar P; Wong JSH; Mathew N; Vogel M; Perrone J; Herring AA; Krausz RM; Montaner JSG; Greenwald MK; Maharaj AR
J Addict Med; 2023 Mar-Apr 01; 17(2):233-236. PubMed ID: 36149002
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
[TBL] [Abstract][Full Text] [Related]
19. Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.
Balhara YPS; Singh S; Sarkar S
Subst Use Misuse; 2019; 54(2):307-314. PubMed ID: 30513249
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine/Naloxone (Zubsolv
Heo YA; Scott LJ
CNS Drugs; 2018 Sep; 32(9):875-882. PubMed ID: 30117074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
